Digital therapeutics pioneer GAIA AG has entered an exclusive strategic partnership with Daiichi Sankyo Europe GmbH to commercialize lipodia, a digital therapeutic designed to support adults living with hypercholesterolemia.
The partnership will come into effect once the therapy receives regulatory approval. It combines GAIA’s expertise in automated digital therapeutics with Daiichi Sankyo’s experience in cardiovascular care.
Together, the companies aim to address a major challenge in chronic disease management: helping patients sustain long-term lifestyle changes alongside medication.
Lipodia is a fully automated digital therapeutic that focuses on behavioral and psychological factors linked to cardiovascular risk.
The therapy uses evidence-based behavioral health science and psychotherapeutic methods to guide patients toward healthier lifestyles.
Key features of lipodia include:
By helping patients integrate healthier routines into daily life, the platform aims to complement traditional pharmacological treatments.
Under the agreement, Daiichi Sankyo Europe receives exclusive commercialization rights for lipodia.
The partnership initially focuses on Germany, Europe’s largest healthcare market, with expansion mechanisms for other major European markets.
The collaboration reflects a broader shift toward integrated cardiovascular care, combining medicines with digital interventions.
Cardiovascular diseases remain a major health burden across Europe:
Major risk factors include:
Digital therapeutics like lipodia aim to address these behavioral drivers of disease.
GAIA plans to submit lipodia for reimbursement once results from its pivotal Phase 3 randomized controlled trial (RCT) become available.
If approved, the therapy could be reimbursed through Germany’s DiGA Fast-Track Pathway, which allows physicians to prescribe digital health applications covered by statutory health insurance.
This pathway could significantly improve patient access by integrating digital therapeutics into routine cardiovascular care.
GAIA is a global pioneer in evidence-based digital therapeutics with more than 25 years of experience. The company develops digital therapies across multiple therapeutic areas, including:
Its products have been validated through more than 30 randomized controlled trials and meta-analyses.
With more than 120 years of scientific innovation, Daiichi Sankyo focuses on developing new treatments for diseases with significant unmet medical need.
The company’s research spans areas such as:
By integrating digital therapeutics with pharmaceutical innovation, the company aims to deliver more comprehensive and patient-centered healthcare solutions.
Bottom line:
The GAIA–Daiichi Sankyo partnership signals the growing role of digital therapeutics in cardiovascular care, offering a scalable solution that combines behavioral science, technology, and medicine to help patients better manage high cholesterol and reduce long-term heart disease risk.